| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and nine months ended September 30, 2025 and 2024:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,204,017 |
|
|
$ |
1,850,812 |
|
|
$ |
4,543,279 |
|
|
$ |
4,143,813 |
|
| Research and development personnel expense(1) |
|
|
457,629 |
|
|
|
436,713 |
|
|
|
1,153,412 |
|
|
|
1,412,881 |
|
| General and administrative personnel expense(2) |
|
|
855,089 |
|
|
|
493,144 |
|
|
|
2,157,979 |
|
|
|
1,457,941 |
|
| Administrative and facilities expense(3) |
|
|
972,108 |
|
|
|
644,184 |
|
|
|
2,431,946 |
|
|
|
2,301,840 |
|
| Other income, net |
|
|
(52,270 |
) |
|
|
(40,150 |
) |
|
|
(81,720 |
) |
|
|
(195,065 |
) |
| Total |
|
$ |
3,436,573 |
|
|
$ |
3,384,703 |
|
|
$ |
10,204,896 |
|
|
$ |
9,121,410 |
|
| (1) |
Research
and development personnel costs include employee stock-based compensation expense of $110,239 and $54,018 for the three months ended
September 30, 2025 and 2024, respectively, and $165,572 and $130,722 for the nine months ended September 30, 2025 and 2024, respectively. |
| |
|
| (2) |
General
and administrative personnel costs include employee stock-based compensation expense of $192,808 and $53,725 for the three months
ended September 30, 2025 and 2024, respectively, and $438,118 and $132,905 for the nine months ended September 30, 2025 and 2024,
respectively, and are net of reimbursements received from CorLyst, LLC. |
| |
|
| (3) |
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|